Skip to main content

ESPEROCT (Novo Nordisk Pharmaceuticals Pty Ltd)

Product name
ESPEROCT
Date registered
Evaluation commenced
Decision date
Approval time
144 (175 working days
Active ingredients
turoctocog alfa pegol
Registration type
NCE/NBE
Indication

ESPEROCT, is a long-acting recombinant Factor VIII concentrate indicated for use in previously treated patients with haemophilia A for:

  • Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Peri-operative management of bleeding (surgical prophylaxis)

ESPEROCT does not contain von Willebrand factor, and therefore is not indicated in patients with von Willebrand’s disease.

Help us improve the Therapeutic Goods Administration site